Cencora COR has been making continuous strides in the biotech market. A significant move was its
$4.4 billion acquisition of Retina Consultants, which stimulated the company's 2025 EPS prognosis and diversified its specialty leadership. The substantial rally in COR's stock has been driven by strong revenue growth with
Q4 revenue surging 14.7% to $79.1B, although volatility has been present. The company's Q4 2024 earnings report reflected a solid financial performance with
adjusted EPS beating expectations at $3.34. However,
Walgreens Boots Alliance sold a large portion of their Cencora shares, gathering approximately $1.1 billion of proceeds. Through the strategic acquisitions and robust growth,
analysts generally designate 'Moderate Buy' recommendations and investment groups like Nordea and Range Financial are amplifying their position in Cencora. Despite some downgrades for the price target and concerns about debt management, the company remains ambitious about its future growth prospects.
Cencora COR News Analytics from Wed, 22 May 2024 07:00:00 GMT to Sat, 11 Jan 2025 21:04:45 GMT -
Rating 6
- Innovation 5
- Information 6
- Rumor 2
